Co-hosted by the University of California, San Francisco (UCSF) and the California Prostate Cancer Coalition (CPCC), offers insights into the latest advancements in prostate cancer.
Co-sponsored by UCLA, UCSF, and the Prostate Cancer Foundation (PCF), this conference focuses on PSMA PET imaging, radioligand therapy, and theranostics, featuring leading experts in the field.
Recent studies have focused on the development of genomic tests to better identify aggressive forms of prostate cancer. These tests aim to improve early detection and personalize treatment plans, potentially leading to better patient outcomes.
NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat prostate cancer.
Research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors. This approach tailors treatment to individual genetic profiles, enhancing efficacy.
The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to a new study.
Drugs such as olaparib, rucaparib, niraparib, and talazoparib have been approved for use alongside hormone therapy in treating advanced prostate cancers with specific DNA repair gene mutations.
For Support, please email us at support@endcanceralliance.org or call +1 (925) 306-4404
You can send mail and/or donations to 1630 M Main St #229, Walnut Creek, CA 94596
Copyright © 2025 END PROSTATE CANCER ALLIANCE - All rights reserved
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.